Share

August 2021; 11 (4) Review

The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension

Body Weight

Susan P. Mollan, Abd A. Tahrani, Alexandra J. Sinclair
First published March 3, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001063
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
115

Share

Article Information

vol. 11 no. 4 e504-e507
DOI: 
https://doi.org/10.1212/CPJ.0000000000001063
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received August 24, 2020
  • Accepted January 6, 2021
  • First Published March 3, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Susan P. Mollan, FRCOphth,
    2. Abd A. Tahrani, PhD and
    3. Alexandra J. Sinclair, PhD
  1. Susan P. Mollan, FRCOphth,
    2. Scientific Advisory Boards:

    1. Janssen Neurodiem Invex therapeutics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Heidelberg Engineering, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Neuro-Ophthalmology: Global Trends in Diagnosis, Treatment and Management. Springer, 2019.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Heidelberg Engineering, speaker bureau

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Abd A. Tahrani, PhD and
    3. Scientific Advisory Boards:

    1. Novo Nordisk Eli Lilly BI

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Eli Lilly, Janssen, AZ, BI, NAPP, MSD, Novo Nordisk

    Editorial Boards:

    1. Associate Editor for the European Journal of Endocrinology Senior Editor BMC Endocrine Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novo Nordisk, Eli Lilly, BI, Sanofi, AZ

    Speakers' Bureaus:

    1. Novo Nordisk, Eli Lilly, NAPP, AZ, BI, MSD, Sanofi,

    Other activities:

    1. Impeto Medical Resmed Aptiva

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. The URGO Foundation

    Research Support, Government Entities:

    1. National Institute for Health Research UK

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Alexandra J. Sinclair, PhD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. 1) NIHR Clinician Scientist Fellowship (NIHR-CS-011-028) 2) Medical Research Council, UK (MR/K015184/1).

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Birmingham Neuro-Ophthalmology (SPM), Queen Elizabeth Hospital; Institute of Metabolism and Systems Research (AAT), College of Medical and Dental Sciences, University of Birmingham; Department of Diabetes and Endocrinology (AAT), Queen Elizabeth Hospital, Birmingham; Metabolic Neurology (AJS), Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham; and Department of Neurology (AJS), University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, United Kingdom.
  1. Correspondence
    Ms. Mollan soozmollan{at}doctors.org.uk
View Full Text

Article usage

Article usage: March 2021 to June 2022

AbstractFullPdfSource
Mar 2021476016Highwire
Apr 202118205Highwire
May 202117504Highwire
Jun 202120002Highwire
Jul 202113002Highwire
Aug 20214763814Highwire
Sep 20214452213Highwire
Oct 2021237910Highwire
Nov 2021185217Highwire
Dec 20219046Highwire
Jan 202213312Highwire
Feb 202212511Highwire
Mar 202212847Highwire
Apr 202211278Highwire
May 20228736Highwire
Jun 20228532Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me